Читать книгу Practical Cardiovascular Medicine - Elias B. Hanna - Страница 158

1 1. O’Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 61: e78–140.

2 2. Ibanez B, James S, Agewall S, et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2018; 39: 119–177.

3 3. Thygesen K, Alpert JS, Jaffe AS, et al. Fourth universal definition of myocardial infarction (2018). J Am Coll Cardiol 2018; 72:2231–2264.

4 4. Kannel WB, Abbott RD. Incidence and prognosis of unrecognized myocardial infarction: an update on the Framingham study. N Engl J Med 1984; 311: 1144–7.

5 5. Delewi R, Ijff G, van de Hoef TP, et al. Pathological Q waves in myocardial infarction in patients treated by primary PCI. JACC Cardiovasc Imaging 2013; 6: 324–31.

6 6. Zheng Y, Bainey KR, Tyrrell BD, Brass N, Armstrong PW, Welsh RC. Relationships between baseline Q waves, time from symptom onset, and clinical outcomes in ST-segment–elevation myocardial infarction patients: insights from the Vital Heart Response Registry. Circ Cardiovasc Interv. 2017; 10(11):e005399.

7 7. Topal DG, Lonborg J, Ahtarovski,KA, et al. Association between early Q Waves and reperfusion success in patients with ST-segment-elevation myocardial infarction treated with primary percutaneous coronary intervention: A cardiac magnetic resonance imaging study. Circ Cardiovasc Intv 2017; 10(3): e004467.

8 8. Fefer F, Hod H, Hammerman H, et al. Relation of clinically defined spontaneous reperfusion to outcome in ST-elevation myocardial infarction. Am J Cardiol 2009; 103: 149–53. Analysis of patients with spontaneous ECG reperfusion from ASSENT-4 PCI indicates significantly reduced mortality and MI size (spontaneous ECG reperfusion defined as ST resolution >70%).

9 9. Janssens GN, ven der Hoeven NW, Lemkes JS, et al. 1-year outcomes of delayed versus immediate intervention in patients with transient ST-segment elevation myocardial infarction. JACC Intv 2019; 12(22): 2272–2282.

10 10. Fibrinolytic Therapy Trialists’ (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994; 343: 311–22.

11 11. Strauss DG, Loring Z, Selvester RH, et al. Right, but not left, bundle branch block is associated with large anteroseptal scar. J Am Coll Cardiol 2013; 62: 959–67.

12 12. Neeland IJ, Kontos MC, de Lemos JA. Evolving considerations in the management of patients with left bundle branch block and suspected myocardial infarction. J Am Coll Cardiol 2012; 60: 96–105.

13 13. Jain S, Ting HT, Bell M, et al. Utility of left bundle branch block as a diagnostic criterion for acute myocardial infarction. Am J Cardiol 2011; 107: 1111–16.

14 14. Chang AM, Shofer FS, Tabas JA, Magid DJ, McCusker CM, Hollander JE. Lack of association between left bundle-branch block and acute myocardial infarction in symptomatic ED patients. Am J Emerg Med 2009; 27: 916–21.

15 15. Rokos IV, Farkouh ME, Reiffel J, et al. Correlation between index electrocardiographic patterns and pre-intervention angiographic findings: Insights from the HORIZONS-AMI trial. Cath Cardiovasc Interv 2012; 79: 1092–8.

16 16. Hanna EB, Lathia VN, Ali M, Deschamps EH. New or presumably new left bundle branch block in patients with suspected acute coronary syndrome: Clinical, echocardiographic, and electrocardiographic features from a single-center registry. J Electrocardiol. 2015; 48(4):505–511.

17 17. Boersma E, Maas AC, Deckers JW, Simoons ML. Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour. Lancet 1996; 348: 771–5.

18 18. Gruppo Italiano per lo Studio della Streptochinasi nell’Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986; 1: 397–402.

19 19. ISIS- 2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2: 349–60.

20 20. Antman EM, Anbe ET, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST elevation myocardial infarction. J Am Coll Cardiol 2004; 44: 671–719.

21 21. GUSTO-I Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673–82.

22 22. Ross AM, Coyne KS, Moreyra E, et al. Extended mortality benefit of early postinfarction reperfusion. GUSTO-I Angiographic Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries Trial. Circulation 1998; 97: 1549. Outcomes of TIMI 2 flow intermediate between TIMI 0/1 and TIMI 3, but closer to TIMI 0/1.

23 23. Lincoff AM, Topol EJ, Califf RM, et al. Significance of a coronary artery with thrombolysis in myocardial infarction grade 2 flow ‘patency’ (outcome in the Thrombolysis and Angioplasty in Myocardial Infarction trials). Am J Cardiol 1995; 75: 871–6. Intermediate outcomes for TIMI 2 flow (between TIMI 0/1 and TIMI 3).

24 24. Reiner JS, Lundergan CF, Fung A, et al. Evolution of early TIMI 2 flow after thrombolysis for acute myocardial infarction. Circulation 1996; 94: 2441–6. If TIMI 2 flow persists, LV function/wall motion is as poor as TIMI 0–1 flow. IF TIMI 2 flow improves to TIMI 3 flow at 5–7 days, LV function improves, slightly less than TIMI 3 flow.

25 25. Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) Investigators.Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet 1999; 354: 716–22.